Von Willebrand Disease (VWD)

4
Pipeline Programs
2
Companies
6
Clinical Trials
4 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
0
3
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Takeda
TakedaTOKYO, Japan
4 programs
3
VONVENDIPhase 31 trial
Vonicog AlfaPhase 31 trial
rVWFPhase 31 trial
TAK-577N/A1 trial
Active Trials
NCT06173024Available
NCT07129343Recruiting20Est. Nov 2027
NCT05582993Recruiting24Est. Apr 2030
+1 more trials
Hemab Therapeutics
Hemab TherapeuticsDenmark - Copenhagen
2 programs
1
HMB-002Phase 1/21 trial
Clinical outcomes of patients with VWD, Type 1N/A1 trial
Active Trials
NCT06610201Recruiting200Est. Jun 2026
NCT06754852Recruiting108Est. Jul 2027

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
TakedaVONVENDI
TakedaVonicog Alfa
TakedarVWF
Hemab TherapeuticsHMB-002
Hemab TherapeuticsClinical outcomes of patients with VWD, Type 1

Clinical Trials (6)

Total enrollment: 390 patients across 6 trials

NCT07129343TakedaVONVENDI

A Study of Recombinant Von Willebrand Factor (rVWF) in Chinese Participants With Von Willebrand Disease (vWD)

Start: Oct 2025Est. completion: Nov 202720 patients
Phase 3Recruiting
NCT05582993TakedaVonicog Alfa

A Study of Vonicog Alfa (rVWF) in Children With Severe Von Willebrand Disease (vWD)

Start: Nov 2024Est. completion: Apr 203024 patients
Phase 3Recruiting
NCT03879135TakedarVWF

A Study of Recombinant Von Willebrand Factor (rVWF) in Pediatric and Adult Participants With Severe Von Willebrand Disease (VWD)

Start: Apr 2019Est. completion: Jan 202538 patients
Phase 3Completed
NCT06754852Hemab TherapeuticsHMB-002

A Study Assessing HMB-002 in Participants With Von Willebrand Disease

Start: Feb 2025Est. completion: Jul 2027108 patients
Phase 1/2Recruiting
NCT06173024TakedaTAK-577

Post Trial Access Program of TAK-577 for Von Willebrand Disease (VWD)

N/AAvailable
NCT06610201Hemab TherapeuticsClinical outcomes of patients with VWD, Type 1

A Study of Bleeding and Treatment in Participants With Von Willebrand Disease

Start: Aug 2024Est. completion: Jun 2026200 patients
N/ARecruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 late-stage (Phase 3) programs — potential near-term approvals
4 actively recruiting trials targeting 390 patients
2 companies competing in this space